Medical expert offers four-step solution.
Like all internal body maladies, breaking kidney stones is a challenge but one that both patients and physicians can measure up to.
“Beating stone disease is indeed a challenge, but it is a challenge that we can measure up through dietary manipulation, lifestyle changes, paying attention to adequate hydration day in and day out, and recognition of the importance of inhibitory substances in the prevention of stone formation,” Dr. Dennis Serrano said during the TASCIT Sci-Tech Summit dubbed “Cutting Edge”.
The tech summit unveiled the advanced technology in kidney stone management and the pioneering research and development behind Biomedis’ potassium citrate. It was the first of its kind in the pharmaceutical and medical sector.
Doctor Serrano stressed that the use of potassium citrate for inhibition of growth and aggregation of calcium phosphate crystals, and for the treatment of uric acid stones that may occur concurrently with or without calcium stones. Potassium citrate can also be used to prevent the recurrence of calcium oxalate and uric acid stones, which comprise about 85 percent to 90 percent of kidney stones, he pointed out
“The use of potassium citrate in preventing stone recurrence is not new to us. For decades, we have prescribed using citrate in solution for patients with recurrent stones. But these are formulations that are both cumbersome, fraught with compliance issues and with adverse events specifically gastrointestinal side effects and erratic serum levels,” he added.
Serrano pointed out that what is needed is a formulation that is stable enough for constant controlled release and friendly to the gastrointestinal tract.
And this, said Unilab senior vice president for R&D, Dr. Kennie Dee, is why Biomedis, a division of United Laboratories Inc., came up with potassium citrate wax matrix extended release potassium citrate tablets.
“The potassium citrate tablets are formulated as extended release wax matrix tablets, which improve patient compliance by reducing gastric irritation. In addition, a more constant level of citrate excretion is maintained throughout the day,” Doctor Dee said.
USP dissolution requirements ensure that the potassium citrate is released from the tablet gradually to allow a constant level of citrate excretion over an extended period as compared to immediate release formulations.
Biomedis’ TASCIT (potassium citrate ER) is classified by the USFDA as a GRAS material, which stands for “Generally Regarded as Safe”.[pq]Unilab vowed to make the technology behind the new kidney stone therapy as patient-friendly as possible.[/pq]
“As the makers of extended-release potassium citrate tablets, it is our commitment to make use of technology in a way that would be most helpful to our partners in the medical community and most advantageous to the Filipino patient. This is why we wanted to share with you the exciting story behind our product with the aid of advance technology,” said Albert Poblete, general manager of Biomedis Inc.
The hologram presentation is a pioneering feature of the summit attended by over 1,500 doctors. This technology enabled the event to be beamed simultaneously to three locations: SMXAura Convention Center in Taguig, Robinsons Summit Ridge Hotel in Tagaytay City, and Marco Polo Hotel in Cebu.
Serrano discussed the history, statistics and technology involved in kidney stones management. According to him, an estimated 10 percent of all people will have a kidney stone at some point in their lives, with peak incidence rising between the ages of 20 to 40 years old.
Doctor Dee demonstrated how the potassium citrate particles in TASCIT are entrapped in a waxy matrix, and then slowly released from the wax tablet. Since waxes are not water soluble, the insoluble wax matrix tablet remains intact as it passes through the gastro-intestinal tract.
“TASCIT has a unique patented process developed using the Synapse technology for efficient and consistent production of potassium citrate ER wax matrix tablets and which allows us to ensure therapeutic benefit to the patients,” he said.